Mirum Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher Peetz
- Full Time Employees
- 433
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 989 East Hillsdale Boulevard Foster City CA United States of America 94404
- IPO Date
- Jul 18, 2019
- CIK
- 0001759425
- Website
- mirumpharma.com
- Similar Companies
- Business
- Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for severe rare and orphan diseases, particularly those affecting the liver. The company’s flagship product, LIVMARLI (maralixibat), an ileal bile acid transporter (IBAT) inhibitor, is approved in the United States and Europe for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older (two months and older in Europe). LIVMARLI also holds U.S. approval for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients 12 months and older, and European approval for PFIC patients three months and older. Beyond LIVMARLI, Mirum is advancing Volixibat, another IBAT inhibitor, through late-stage clinical studies for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), having reported positive interim results for PBC showing significant improvements in pruritus and fatigue. The company's pipeline further includes CHOLBAM (cholic acid) capsules for bile acid synthesis disorders and CHENODAL (chenodiol) tablets for cerebrotendinous xanthomatosis (CTX), both FDA-approved. Mirum also has MRM-3379, a PDE4D inhibitor, in Phase 2 development for Fragile X syndrome. Mirum Pharmaceuticals, established in 2018 and headquartered in Foster City, California, generates revenue primarily from product sales across key markets including the United States and Europe. The company reported strong financial performance in 2024 and Q3 2025, with increasing product sales and a move to net profitability, leading to raised revenue guidance for 2025.
Company News
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
Mirum Pharmaceuticals’ LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
Mirum wins FDA approval for Atebrioz
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum's liver infection drug lowers virus levels in late-stage study
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $137.31
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva